Form 4: Neurocrine Biosciences Chief Regulatory Officer Executes Stock Option and Sells Shares Under 10b5-1 Plan

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 21, 2024, Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, exercised a non-qualified stock option for 5,000 shares at a price of $103.52 per share.
• Simultaneously, Delaet sold 5,000 shares of common stock at an average price of $145.064, with prices ranging from $145.00 to $145.24.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 29, 2023.
• Following these transactions, Delaet directly owns 7,507 shares of Neurocrine Biosciences common stock and holds options for 27,049 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing simply reports routine transactions under a pre-existing trading plan. There is no indication of positive or negative news for the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating a planned and transparent approach to stock sales.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock transactions and avoid potential insider trading accusations, similar to practices seen at companies like Pfizer or Amgen.
• The vesting schedule of the stock options, with 1/48th vesting monthly, is a typical arrangement for executive compensation packages, aligning with industry norms observed at companies such as Biogen and Gilead Sciences.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the pre-planned nature of the sales mitigates concerns about insider information being used.

Key Dates